Corcept Therapeutics Incorporated (CORT) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Gross Margin ⢠OpEx Pressure ⢠Cash Flow Swing CORT has excellent gross margins and a strong balance sheet, but heavy operating spending drove a sharp quarterly loss and negative cash flow, making the stock dependent on a sustained return to operating efficiency despite rich valuation multiples.
Price Behavior
Key Price Behavior Insights: ⢠Breakout streak ⢠Strong momentum ⢠Pullback risk Support Level: $70-$71 Resistance Level: $74.89 Over the last month, CORT has been in a strong uptrend with breakouts above $60 and $70, but the rapid move to $72.62 and recent $74.89 peak leaves it stretched and vulnerable to a short-term pullback toward $70-$68.
Sentiment & News
Key News Insights: ⢠Revenue raise ⢠NDA resubmission ⢠ASCO data Corcept's stronger 2026 sales outlook, relacorilant NDA resubmission plans, and new ASCO data suggest improving growth momentum and multiple near-term catalysts.
AI Summary
CORT now looks less like a speculative biotech and more like a profitable commercial franchise with strong cash generation and near-term upside from relacorilant's NDA resubmission and ovarian-cancer data, but at current levels the stock is priced for execution so litigation, regulatory delays, and any miss on growth or expenses could quickly re-rate it lower.
Description
Corcept Therapeutics is a U.S.-based biopharmaceutical company that discovers, develops and commercializes drugs for severe metabolic, oncologic and neuropsychiatric conditions. It markets Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushingâs syndrome in adults with type 2 diabetes or glucose intolerance who have not had successful surgery or are ineligible, and has clinical-stage programs including relacorilant for Cushingâs and combination studies with nab-paclitaxel in advanced ovarian tumors, alongside separate programs targeting prostate cancer, antipsychotic-induced weight gain and FKBP5-related diagnostics. Founded in 1998, the company is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 8 | Jun 15 | CORT | Corcept Therapeutics Incorporated | Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active. | Active | +0.0% |